We need better data on how to manage myocarditis in athletes

Halle M Binzenhöfer L Mahrholdt H , et al. Myocarditis in athletes – a clinical perspective. Eur J Prev Cardiol, Epub ahead of print 3 March 2020. DOI: 10.1177/2047487320909670

Eichhorn C Bière L Schnell F , et al. Myocarditis in athletes is a challenge: Diagnosis, risk stratification, and uncertainties. JACC Cardiovasc Imaging 2020; 13: 494–507.

Maron BJ Thompson PD Ackerman MJ , et al. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: A scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: Endorsed by the American College of Cardiology Foundation. Circulation 2007; 115: 1643–1655.

Sheikh N Papadakis M Ghani S , et al. Comparison of electrocardiographic criteria for the detection of cardiac abnormalities in elite Black and White athletes. Circulation 2014; 129: 1637–1649.

Siegel AJ Silverman LM Evans WJ. Elevated skeletal muscle creatine kinase MB isoenzyme levels in marathon runners. JAMA 1983; 250: 2835–2837.

Shave R Baggish A George K , et al. Exercise-induced cardiac troponin elevation: Evidence, mechanisms, and implications. J Am Coll Cardiol 2010; 56: 169–176.

Neilan TG Januzzi JL Lee-Lewandrowski E , et al. Myocardial injury and ventricular dysfunction related to training levels among nonelite participants in the Boston marathon. Circulation 2006; 114: 2325–2333.

Abergel E Chatellier G Hagege AA , et al. Serial left ventricular adaptations in world-class professional cyclists: Implications for disease screening and follow-up. J Am Coll Cardiol 2004; 44: 144–149.

La Gerche A Rakhit DJ Claessen G. Exercise and the right ventricle: A potential Achilles’ heel. Cardiovasc Res 2017; 113: 1499–1508.

Pelliccia A Solberg EE Papadakis M , et al. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: Position statement of the Sport Cardiology Section of the European Association Of Preventive Cardiology (EAPC). Eur Heart J 2019; 40: 19–33.

Maron BJ Udelson JE Bonow RO , et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task force 3: Hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: A scientific statement from the American Heart Association and American College of Cardiology. Circulation 2015; 132: e273–e280.